Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats
-
Xuebing Cao [1] ; Dongzhi Hou [2] ; Lei Wang [4] ; Sai Li [3] ; Shengang Sun [1] ; Qineng Ping [3] ; Yan Xu [1]
-
[1] Huazhong University of Science and Technology
Huazhong University of Science and Technology
China
-
[2] Guangdong Pharmaceutical University
Guangdong Pharmaceutical University
China
-
[3] China Pharmaceutical University
China Pharmaceutical University
China
-
[4] Weifang People's Hospital Department of Neurology
-
- Localización: Biological Research, ISSN-e 0717-6287, ISSN 0716-9760, Nº. 49, 2016, 9 págs.
- Idioma: inglés
- Enlaces
-
Resumen
Chitosan, the N-deacetylated derivative of chitin, is a cationic polyelectrolyte due to the presence of amino groups, one of the few occurring in nature. The use of chitosan in protein and drug delivery systems is being actively researched and reported in the literature RESULTS: In this study, we used chitosan-coated levodopa liposomes to investigate the behavioral character and the expression of phosphorylated extracellular signal-regulated kinase (ERK1/2), dopamine- and cAMP-regulated phos-phoprotein of 32 kDa (DARPP-32) and FosB/AFosB in striatum of rat model of levodopa-induced dyskinesia (LID). We found that scores of abnormal involuntary movement (AIM) decreased significantly in liposome group (P < 0.05), compared with levodopa group. Levels of phospho-ERK1/2, phospho-Thr34 DARPP-32 and FosB/AFosB in striatum decreased significantly in liposome group lesion side compared with levodopa group (P < 0.05). However, both of two groups above have significantly differences compared with the control group (P < 0.05 CONCLUSION: Chitosan-coated levodopa liposomes may be useful in reducing dyskinesias inducing for Parkinson disease. The mechanism might be involved the pathway of signaling molecular phospho-ERK1/2, phospho-Thr34 DARPP-32 and AFosB in striatum
